Adaptam Therapeutics

The company develops antibody-based therapies, including antibody-drug conjugates (ADCs) and bispecific antibodies, that target the immunosuppressive myeloid tumor microenvironment. These therapies focus on novel targets such as glycan-binding proteins and Siglecs expressed in tumor-associated macrophages. The technology aims to provide more effective treatment options for oncology patients by unlocking immune responses against cancer.